Details of the Drug Formulations

General Information of Drug (ID: DMWFJTR)

Drug Name
Linagliptin Drug Info
Synonyms Ondero; BI 1356; BI-1356; Ondero (TN); BI-1356-BS; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Indication
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [1]
Type 2 diabetes 5A11 Approved [2]
Type-2 diabetes 5A11 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Cross-matching ID
PubChem CID
10096344
ChEBI ID
CHEBI:68610
CAS Number
668270-12-0
TTD ID
D02EYG
VARIDT ID
DR00745
INTEDE ID
DR2673
ACDINA ID
D01209

Full List of Drug Formulations Containing This Drug

Linagliptin 5mg tablet
Company Formulation ID FDA Description
Boehringer Ingelheim F23211 Mannitol; Pregelatinized Starch; Corn Starch; Copovidone; Magnesium Stearate; Hypromellose, Titanium Dioxid; Talc; Polyethylene Glycol; Red Ferric Oxide
------------------------------------------------------------------------------------

References

1 Linagliptin FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6318).
4 ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.